New cell therapy CPTX2309 enters human testing for autoimmune diseases
Disease control
Recruiting now
This early-stage study tests the safety of a new drug called CPTX2309 in healthy people and those with moderate to severe rheumatoid arthritis or lupus. Researchers will give the drug through a vein and watch for side effects, changes in lab tests, and how the body responds. The …
Phase: PHASE1 • Sponsor: Capstan Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:51 UTC